Toxicities of Axitinib, Sunitinib and Temsirolimus: Implications for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer

References

• Bray F , FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Dabestani S , ThorstensonA, LindbladP, HarmenbergU, LjungbergB, LundstamS. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J. Urol.34(8), 1081–1086 (2016).
   PubMed Web of Science ®Google Scholar
• Ljungberg B , AlbigesL, Abu-GhanemYet al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur. Urol.75(5), 799–810 (2019).
   PubMed Web of Science ®Google Scholar
• Bhojani N , JeldresC, PatardJ-Jet al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur. Urol.53(5), 917–930 (2008).
   PubMed Web of Science ®Google Scholar
• Gunnarsson O , PfanzelterNR, CohenRB, KeefeSM. Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Cancer Manag. Res.7, 65–73 (2015).
   PubMed Web of Science ®Google Scholar
• Sehdev S . Sunitinib toxicity management—a practical approach. Can. Urol. Assoc. J.10(11–12 Suppl. 7), S248–S251 (2016).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, CellaDet al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med.369(8), 722–731 (2013).
   PubMed Web of Science ®Google Scholar
• Méndez-Vidal MJ , MartínezOrtega E, MontesaPino Á, PérezValderrama B, VicianaR. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev.31(1), 19–27 (2012).
   Google Scholar
• Ravaud A . Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist16(Suppl. 2), 32–44 (2011).
   PubMed Web of Science ®Google Scholar
• Pal S , GongJ, MhatreSKet al. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer19(1), 548–548 (2019).
   PubMedGoogle Scholar
• Poprach A , PavlikT, MelicharBet al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann. Oncol.23(12), 3137–3143 (2012).
   PubMed Web of Science ®Google Scholar
• Bono P , RautiolaJ, UtriainenT, JoensuuH. Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol.50(4), 569–573 (2011).
   PubMed Web of Science ®Google Scholar
• Schmidinger M , VoglUM, BojicMet al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117(3), 534–544 (2011).
   PubMed Web of Science ®Google Scholar
• Donskov F , MichaelsonMD, PuzanovIet al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br. J. Cancer113(11), 1571–1580 (2015).
   PubMed Web of Science ®Google Scholar
• Boegemann M , HubbeM, ThomaidouDet al. Sunitinib treatment modification in first-line metastatic renal cell carcinoma: analysis of the STAR-TOR registry. Anticancer Res.38(11), 6413–6422 (2018).
   PubMed Web of Science ®Google Scholar
• Heng DYC , XieW, ReganMMet al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol.27(34), 5794–5799 (2009).
   PubMed Web of Science ®Google Scholar
• Nah EH , KimS, ChoS, ChoHI. Complete blood count reference intervals and patterns of changes across pediatric, adult, and geriatric ages in Korea. Ann. Lab. Med.38(6), 503–511 (2018).
   PubMed Web of Science ®Google Scholar
• McHugh ML . The chi-square test of independence. Biochem. Med. (Zagreb)23(2), 143–149 (2013).
   PubMed Web of Science ®Google Scholar
• Lacouture ME , WuS, RobertCet al. Evolving strategies for the management of hand–foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist13(9), 1001–1011 (2008).
   PubMed Web of Science ®Google Scholar
• Lacouture ME , ReillyLM, GeramiP, GuitartJ. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann. Oncol.19(11), 1955–1961 (2008).
   PubMed Web of Science ®Google Scholar
• Erber R , ThurnherA, KatsenADet al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J.18(2), 338–340 (2004).
   PubMed Web of Science ®Google Scholar
• Fischer A , WuS, HoAL, LacoutureME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest. New Drugs31(3), 787–797 (2013).
   PubMed Web of Science ®Google Scholar
• Shah DR , ShahRR, MorganrothJ. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf.36(6), 413–426 (2013).
   PubMed Web of Science ®Google Scholar
• Dy GK , AdjeiAA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J. Clin.63(4), 249–279 (2013).
   PubMed Web of Science ®Google Scholar
• Pfizer Laboratories Div Pfizer Inc . Inlyta® perscribing information. (2020). http://labeling.pfizer.com/ShowLabeling.aspx?id=759
   Google Scholar
• Schmid TA , GoreME. Sunitinib in the treatment of metastatic renal cell carcinoma. Ther. Adv. Urol.8(6), 348–371 (2016).
   PubMedGoogle Scholar
• Hudes G , CarducciM, TomczakPet al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Hutson TE , EscudierB, EstebanEet al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.32(8), 760–767 (2014).
   PubMed Web of Science ®Google Scholar
• Boegemann M , BedkeJ, SchostakMet al. Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): third interim results of the non-interventional study PAZOREAL. J. Clin. Oncol.37(Suppl. 15), 4574–4574 (2019).
   Google Scholar
• Sternberg CN , DavisID, MardiakJet al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol.28(6), 1061–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Puzanov I , MichaelsonMD, CohenDP, LiS, BurnettP, DesaiJ. Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST). J. Clin. Oncol.29(Suppl. 15), e21113–e21113 (2011).
   Google Scholar
• Michaelson MD , CohenDP, LiSet al. Hand–foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). J. Clin. Oncol.29(Suppl. 7), 320–320 (2011).
   Web of Science ®Google Scholar
• Di Fiore F , RigalO, MenagerC, MichelP, PfisterC. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br. J. Cancer105(12), 1811–1813 (2011).
   PubMed Web of Science ®Google Scholar
• Escudier B , GoreM. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D11(2), 113–126 (2011).
   PubMedGoogle Scholar
• Rini BI , EscudierB, TomczakPet al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet378(9807), 1931–1939 (2011).
   PubMed Web of Science ®Google Scholar
• Azam C , ClarazP, ChevreauCet al. Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors. Eur. J. Clin. Pharmacol.76(4), 579–587 (2020).
   PubMed Web of Science ®Google Scholar